John Yates

Summary

Affiliation: Takeda Global Research and Development Center
Country: USA

Publications

  1. ncbi request reprint Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment
    John Yates
    Merck and Company, Inc, Upper Gwynedd, Pennsylvania, USA
    Obstet Gynecol 103:440-6. 2004
  2. ncbi request reprint Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study
    Susan Greenspan
    Department of Medicine, University of Texas Southwestern Medical School, Dallas 75216, USA
    Mayo Clin Proc 77:1044-52. 2002
  3. ncbi request reprint Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study
    Michael R McClung
    Oregon Osteoporosis Center, 5050 Northeast Hoyt, Suite 651, Portland, Oregon 97213, USA
    J Clin Endocrinol Metab 89:4879-85. 2004
  4. ncbi request reprint Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
    Erland Erdmann
    Medizinische Klinik III der Universität zu Köln Kerpener Str 62, D 50937 Koln, Germany
    Diabetes Care 30:2773-8. 2007

Collaborators

Detail Information

Publications4

  1. ncbi request reprint Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment
    John Yates
    Merck and Company, Inc, Upper Gwynedd, Pennsylvania, USA
    Obstet Gynecol 103:440-6. 2004
    ..The objective of this study was to evaluate the association between HT cessation and hip fracture risk...
  2. ncbi request reprint Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study
    Susan Greenspan
    Department of Medicine, University of Texas Southwestern Medical School, Dallas 75216, USA
    Mayo Clin Proc 77:1044-52. 2002
    ..To compare the upper gastrointestinal (GI) tract tolerability of once-weekly oral alendronate, 70 mg, and placebo...
  3. ncbi request reprint Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study
    Michael R McClung
    Oregon Osteoporosis Center, 5050 Northeast Hoyt, Suite 651, Portland, Oregon 97213, USA
    J Clin Endocrinol Metab 89:4879-85. 2004
    ..5, 10.3, and 8.9% of women taking placebo, 2.5 mg alendronate, or 5 mg alendronate daily, respectively. Therapy with alendronate is an effective and promising strategy for the prevention of postmenopausal osteoporosis...
  4. ncbi request reprint Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
    Erland Erdmann
    Medizinische Klinik III der Universität zu Köln Kerpener Str 62, D 50937 Koln, Germany
    Diabetes Care 30:2773-8. 2007
    ..We analyzed the heart failure cases to assess the effects of treatment on morbidity and mortality after reports of serious heart failure...